Neurocrine Biosciences (NBIX) Non Operating Income (2010 - 2026)

Neurocrine Biosciences has reported Non Operating Income for 17 years, with the latest figure at $53.4 million in Q1 2026.

• For the quarter ending Q1 2026, Non Operating Income rose 700.0% year-over-year to $53.4 million; the trailing twelve-month figure through Mar 2026 stood at $148.6 million (up 619.58% YoY), and the FY2025 full-year result was $86.3 million, up 202.13% from the prior year.
• Non Operating Income for Q1 2026 stood at $53.4 million, up from $28.5 million in the prior quarter.
• The five-year high for Non Operating Income was $53.4 million in Q1 2026, with the low at -$78.0 million in Q2 2022.
• Historically, Non Operating Income has averaged $6.0 million across 5 years, with a median of $13.9 million in 2025.
• Annual changes were most pronounced in 2022 — Non Operating Income sank 1371.7% — and 2025, when it jumped 712.31%.
• Neurocrine Biosciences' Non Operating Income stood at $14.5 million in 2022, then soared by 230.34% to $47.9 million in 2023, then plunged by 56.99% to $20.6 million in 2024, then soared by 38.35% to $28.5 million in 2025, then jumped by 87.37% to $53.4 million in 2026.
• The last three Non Operating Income figures came in at $53.4 million (Q1 2026), $28.5 million (Q4 2025), and $52.8 million (Q3 2025), per Business Quant data.